Nabriva expects to price IPO of 9 million ADSs at $10.50 per ADS

Bookrunners Leerink, RBC, co-managers Needham, Wedbush PacGrow assist

By Devika Patel

Knoxville, Tenn., Sept. 17 – Nabriva Therapeutics AG will sell 9 million American Depositary Shares in its initial public offering with a 30-day greenshoe of 1.35 million additional ADSs, according to a Form F-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced on June 18.

The ADSs will be sold at an expected price of $10.50 apiece. Each ADS will represent 1/10 of a common share.

Leerink Partners and RBC Capital Markets are the bookrunning managers; Needham & Co. and Wedbush PacGrow are the co-managers.

Proceeds will be used for clinical development, working capital and other general corporate purposes.

The biopharmaceutical company is based in Vienna, Austria. It expects the ADSs to trade on the Nasdaq under the symbol “NBRV.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.